Ignite Creation Date:
2024-05-06 @ 7:15 PM
Last Modification Date:
2024-10-26 @ 3:03 PM
Study NCT ID:
NCT05945849
Status:
RECRUITING
Last Update Posted:
2024-03-07
First Post:
2023-07-06
Brief Title:
CD33KO-HSPC Infusion Followed by CART-33 Infusions for RefractoryRelapsed AML
Sponsor:
University of Pennsylvania
Organization:
University of Pennsylvania
Study Overview
Official Title:
Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD33 Linked to TCRζ And 4-1BB Signaling Domains In Combination With CD33KO-HSPC In Subjects With Refractory Or Relapsed Acute Myeloid Leukemia
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CART33
Brief Summary:
The purpose of this study is to provide a new type of treatment for AML This treatment combines a new type of stem cell transplant along with treatment using chimeric antigen receptor CAR T cells that have been engineered to recognize and attack your AML cells
The first treatment is a modified stem cell transplant using blood-forming stem cells donated from a healthy donor From the same donor we will also make CAR T-cells which are leukemia fighting cells which will be given to the patient via an infusion into the vein after the transplanted stem cells have started to grow healthy blood cells The modification of the stem cell transplant means that the healthy bone marrow cells will be invisible to the CAR T-cells that are trying to kill the leukemia cells
The first treatment is a modified stem cell transplant using blood-forming stem cells donated from a healthy donor From the same donor we will also make CAR T-cells which are leukemia fighting cells which will be given to the patient via an infusion into the vein after the transplanted stem cells have started to grow healthy blood cells The modification of the stem cell transplant means that the healthy bone marrow cells will be invisible to the CAR T-cells that are trying to kill the leukemia cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None